SOURCE: Premier Biomedical, Inc.

October 03, 2013 08:00 ET

Premier Biomedical CEO Presents at KCD Financial Conference

MILWAUKEE, WI--(Marketwired - Oct 3, 2013) - On September 23, 2013, Premier Biomedical, Inc. (OTCQB: BIEI) President and CEO, William A. Hartman, was a featured speaker at the annual KCD Financial Conference in Milwaukee, Wisconsin. The audience in attendance represented affiliated financial agents from across the country.

Mr. Hartman discussed the company's exciting research and development partnerships with the U.S. Department of Defense and the University of Texas at El Paso to develop an innovative method to treat cancer, Alzheimer's disease, and traumatic brain injury/concussion leading to clinical depression and suicidal ideation. As part of the meeting material, Mr. Hartman also shared previously released information on the company's recent testing of its breast cancer drug, which resulted in an astounding 100% survival rate in mice with breast cancer receiving Premier Biomedical's non-toxic immune system manipulation treatment as well as the fact that the mice gained weight during the test, a sign of increased overall health.

Mr. Hartman remarked on his appearance at the conference, "I am very grateful for the intense interest and attention shown to us at KCD Financial's Annual Conference in Milwaukee. I was very impressed with the professionalism and general level of knowledge displayed in discussions with agents and guests during and after the conference. The demonstrated stock price appreciation experienced by other companies that attended prior year's conferences gives me confidence that Premier Biomedical Inc.'s stable growth strategy combined with other activities that increase our targeted exposure to the investing public can result in a very promising future for our company."

The official article released by the University of Texas at El Paso (UTEP) disclosing the results of the breast cancer study in which a 100% survival rate was reported in mice treated with Premier Biomedical, Inc.'s immune system manipulation drug is viewable here:

Video of the joint US Army - Premier Biomedical, Inc. press conference in which Lt. Col. Dr. Shawna Scully, MC, DO, Chief of Neurology at the William Beaumont Army Medical Center discusses a potential cure for Traumatic Brain Injury, Clinical Depression, and Suicidal Ideation is available for viewing here:

The trip to Milwaukee followed a week-long trip to El Paso by a team of PBI Directors where meetings were held with State Senator Jose Rodriguez, a field representative of U.S. Congressman Pete Gallego, officers from the Texas Tech University, the El Paso Chamber of Commerce, Emma Schwartz, President of the Medical Center of the Americas, Albert DiRienzo, Executive Director of the Biomedical Institute of the Americas, and a technical review meeting with UTEP and the William Beaumont Army Medical Center.

About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, in collaboration with the University of Texas at El Paso and US Department of Defense, specifically targeting the treatment of Alzheimer's Disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier is headquartered in El Paso, Texas, with offices in Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI."

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

Contact Information